Eiger BioPharmaceuticals (EIGR) Short Interest Ratio & Short Volume → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free EIGR Stock Alerts Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Eiger BioPharmaceuticals Short Interest DataCurrent Short Volume29,800 sharesPrevious Short Volume33,600 sharesChange Vs. Previous Month-11.31%Dollar Volume Sold Short$149,149.00Short Interest Ratio / Days to Cover0.3Last Record DateMarch 31, 2024Outstanding Shares1,480,000 sharesFloat Size1,310,000 sharesShort Percent of Float2.27%Today's Trading Volume137,800 sharesAverage Trading Volume103,866 sharesToday's Volume Vs. Average133% Short Selling Eiger BioPharmaceuticals ? Sign up to receive the latest short interest report for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEIGR Short Interest Over TimeEIGR Days to Cover Over TimeEIGR Percentage of Float Shorted Over Time Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. Eiger BioPharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202429,800 shares $149,149.00 -11.3%2.3%0.3 $5.01 3/15/202433,600 shares $172,704.00 -18.8%2.6%2.8 $5.14 2/29/202441,400 shares $231,840.00 -2.1%3.2%4.2 $5.60 2/15/202442,300 shares $240,264.00 +27.0%3.2%4.7 $5.68 1/31/202433,300 shares $216,783.00 +14.0%2.5%3.8 $6.51 1/15/202429,200 shares $214,912.00 -7.3%2.2%2.8 $7.36 Get the Latest News and Ratings for EIGR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 12/31/202331,500 shares $212,152.50 -97.1%2.1%2.9 $6.74 12/15/20231,070,000 shares $236,363.00 -7.0%N/A3.6 $0.22 11/30/20231,150,000 shares $391,115.00 +13.9%N/A3.5 $0.34 11/15/20231,010,000 shares $358,449.00 -5.6%N/A3.1 $0.35 10/31/20231,070,000 shares $279,270.00 No ChangeN/A3.1 $0.26 10/15/20231,070,000 shares $268,035.00 -7.8%N/A3.3 $0.25 9/30/20231,160,000 shares $353,800.00 -7.2%N/A4 $0.31 9/15/20231,250,000 shares $504,250.00 -0.8%N/A2.8 $0.40 8/31/20231,260,000 shares $1.09 million +4.1%N/A2.9 $0.86 8/15/20231,210,000 shares $738,100.00 +0.8%N/A2.7 $0.61 7/31/20231,200,000 shares $816,000.00 -9.8%N/A2.6 $0.68 7/15/20231,330,000 shares $1.04 million +26.7%N/A2.9 $0.78 6/30/20231,050,000 shares $739,200.00 -55.5%N/A2.1 $0.70 6/15/20232,360,000 shares $2.30 million -4.5%N/A6.2 $0.97 5/31/20232,470,000 shares $2.77 million +1.2%N/A7.4 $1.12 5/15/20232,440,000 shares $3.07 million -3.2%N/A7 $1.26 4/30/20232,520,000 shares $2.60 million -7.0%N/A4.7 $1.03 4/15/20232,710,000 shares $2.95 million +9.3%N/A4.3 $1.09 3/31/20232,480,000 shares $2.22 million +10.7%N/A3.7 $0.90 3/15/20232,240,000 shares $2.64 million +12.6%N/A3 $1.18 2/28/20231,990,000 shares $3.74 million -7.9%N/A1.7 $1.88 2/15/20232,160,000 shares $4.82 million +56.5%N/A1.9 $2.23 1/31/20231,380,000 shares $2.62 million +15.0%N/A1.2 $1.90 1/15/20231,200,000 shares $1.80 million -21.1%N/A1.3 $1.50 12/30/20221,520,000 shares $1.79 million -3.2%N/A1.7 $1.18 12/15/20221,570,000 shares $2.03 million +8.3%N/A2 $1.29 11/30/20221,450,000 shares $6.58 million -13.2%N/A2.5 $4.54 11/15/20221,670,000 shares $7.63 million -8.2%N/A4.9 $4.57 10/31/20221,820,000 shares $9.30 million -3.7%N/A5.3 $5.11 10/15/20221,890,000 shares $11.14 million -2.1%N/A5.7 $5.90 9/30/20221,930,000 shares $14.53 million +13.5%N/A6.3 $7.53 9/15/20221,700,000 shares $12.84 million -0.6%N/A5.4 $7.55 8/31/20221,710,000 shares $14.12 million -10.9%N/A5.3 $8.26 8/15/20221,920,000 shares $18.55 million -6.3%N/A5.9 $9.66This company has increased its dividend every year for 54 years (Ad)There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.Click here to get them (for Free). EIGR Short Interest - Frequently Asked Questions What is Eiger BioPharmaceuticals' current short interest? Short interest is the volume of Eiger BioPharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 29,800 shares of EIGR short. 2.27% of Eiger BioPharmaceuticals' shares are currently sold short. Learn More on Eiger BioPharmaceuticals' current short interest. Which institutional investors are shorting Eiger BioPharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Eiger BioPharmaceuticals: Citadel Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Eiger BioPharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.27% of Eiger BioPharmaceuticals' floating shares are currently sold short. Is Eiger BioPharmaceuticals' short interest increasing or decreasing? Eiger BioPharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 29,800 shares, a decrease of 11.3% from the previous total of 33,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Eiger BioPharmaceuticals' float size? Eiger BioPharmaceuticals currently has issued a total of 1,480,000 shares. Some of Eiger BioPharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eiger BioPharmaceuticals currently has a public float of 1,310,000 shares. How does Eiger BioPharmaceuticals' short interest compare to its competitors? 2.27% of Eiger BioPharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Eiger BioPharmaceuticals: Revelation Biosciences, Inc. (8.34%), Bionomics Limited (3.17%), Altamira Therapeutics Ltd. (28.13%), SeqLL Inc. (10.87%), Sonoma Pharmaceuticals, Inc. (0.19%), Zhongchao Inc. (0.55%), Agile Therapeutics, Inc. (12.68%), Quoin Pharmaceuticals, Ltd. (0.31%), Dynatronics Co. (0.57%), CohBar, Inc. (0.59%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Eiger BioPharmaceuticals stock? Short selling EIGR is an investing strategy that aims to generate trading profit from Eiger BioPharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eiger BioPharmaceuticals? A short squeeze for Eiger BioPharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EIGR, which in turn drives the price of the stock up even further. How often is Eiger BioPharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EIGR, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Revelation Biosciences Short Squeeze Bionomics Short Squeeze Altamira Therapeutics Short Squeeze SeqLL Short Squeeze Sonoma Pharmaceuticals Short Squeeze Zhongchao Short Squeeze Agile Therapeutics Short Squeeze Quoin Pharmaceuticals Short Squeeze Dynatronics Short Squeeze CohBar Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EIGR) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative